Facile Therapeutics

Organization Address
1025 Alameda de las Pulgas, #116
Belmont, CA 94002

Organization Phone
(650) 264-7876

Biotech and Pharmaceutical

Organization Description
Facile Therapeutics is developing the drug Ebselen as a treatment for Clostridium difficile (C diff) infection (CDI). We believe that this drug can transform the way this devastating disease is treated. One of Facile’s founders has discovered that Ebselen is effective in resolving CDI effects in a mouse model, and published the results in Science Translational Medicine. A critical aspect of this discovery is that Ebselen has already been shown to be safe in humans: it has been used in Phase 2 clinical trials in Japan and the US (for indications not related to C diff), and has shown no serious adverse events. Therefore, the safety of Ebselen in humans has been clinically established. Facile Therapeutics mission is to achieve success in a Phase 2a, Proof-of-Validation clinical study to demonstrate Ebselen can resolve CDI in humans. Because Ebselen has a good clinical safety record, we are in the unusual and advantageous position that the usual IND-enabling and Phase I studies are not required. For success in this straight-to-Phase 2 trial, Facile will develop a clinical plan, source drug for the study, and conduct the study in 50 - 100 patients